Ocular adverse drug reactions

F. W. Fraunfelder

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Drug-induced ocular side effects are described according to recent reports from the literature, the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization (WHO) and the FDA. Adverse events are categorised as certain, probable/likely, possible, unlikely, conditional/unclassified and unassessable/unclassifiable where indicated. Ocular side effects of clinical importance are highlighted with guidelines for recognition, reporting and treatment of adverse drug reactions (ADRs). The current and future status of pharmacovigilance in ocular toxicology is addressed.

Original languageEnglish (US)
Pages (from-to)411-420
Number of pages10
JournalExpert Opinion on Drug Safety
Volume2
Issue number4
DOIs
StatePublished - Jul 1 2003

Fingerprint

Drug-Related Side Effects and Adverse Reactions
Pharmacovigilance
Pharmaceutical Preparations
Toxicology
Registries
Guidelines

Keywords

  • adverse drug reactions (ADRs)
  • ocular side effects
  • ocular toxicology
  • pharmacovigilance

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Ocular adverse drug reactions. / Fraunfelder, F. W.

In: Expert Opinion on Drug Safety, Vol. 2, No. 4, 01.07.2003, p. 411-420.

Research output: Contribution to journalArticle

Fraunfelder, F. W. / Ocular adverse drug reactions. In: Expert Opinion on Drug Safety. 2003 ; Vol. 2, No. 4. pp. 411-420.
@article{eb6b8498b2304d3c93c4ffca7229793a,
title = "Ocular adverse drug reactions",
abstract = "Drug-induced ocular side effects are described according to recent reports from the literature, the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization (WHO) and the FDA. Adverse events are categorised as certain, probable/likely, possible, unlikely, conditional/unclassified and unassessable/unclassifiable where indicated. Ocular side effects of clinical importance are highlighted with guidelines for recognition, reporting and treatment of adverse drug reactions (ADRs). The current and future status of pharmacovigilance in ocular toxicology is addressed.",
keywords = "adverse drug reactions (ADRs), ocular side effects, ocular toxicology, pharmacovigilance",
author = "Fraunfelder, {F. W.}",
year = "2003",
month = "7",
day = "1",
doi = "10.1517/14740338.2.4.411",
language = "English (US)",
volume = "2",
pages = "411--420",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Ocular adverse drug reactions

AU - Fraunfelder, F. W.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Drug-induced ocular side effects are described according to recent reports from the literature, the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization (WHO) and the FDA. Adverse events are categorised as certain, probable/likely, possible, unlikely, conditional/unclassified and unassessable/unclassifiable where indicated. Ocular side effects of clinical importance are highlighted with guidelines for recognition, reporting and treatment of adverse drug reactions (ADRs). The current and future status of pharmacovigilance in ocular toxicology is addressed.

AB - Drug-induced ocular side effects are described according to recent reports from the literature, the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization (WHO) and the FDA. Adverse events are categorised as certain, probable/likely, possible, unlikely, conditional/unclassified and unassessable/unclassifiable where indicated. Ocular side effects of clinical importance are highlighted with guidelines for recognition, reporting and treatment of adverse drug reactions (ADRs). The current and future status of pharmacovigilance in ocular toxicology is addressed.

KW - adverse drug reactions (ADRs)

KW - ocular side effects

KW - ocular toxicology

KW - pharmacovigilance

UR - http://www.scopus.com/inward/record.url?scp=0141818235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141818235&partnerID=8YFLogxK

U2 - 10.1517/14740338.2.4.411

DO - 10.1517/14740338.2.4.411

M3 - Article

VL - 2

SP - 411

EP - 420

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 4

ER -